Valneva and Serum Institute of India Announce Discontinuation of Chikungunya Vaccine License Agreement
MWN-AI** Summary
Valneva SE, a specialty vaccine company, and Serum Institute of India (SII), one of the leading vaccine manufacturers globally, have jointly decided to terminate their licensing agreement for Valneva's promising single-shot chikungunya vaccine. This decision, announced on December 31, 2025, marks a significant shift in Valneva's strategy, allowing the company to regain full control over the vaccine's supply chain and commercialization in high-risk endemic countries. The move aims to enhance accessibility and deployment of the vaccine, particularly in low- and middle-income countries (LMICs), aligning with the funding agreement Valneva had signed with the Coalition for Epidemic Preparedness Innovations (CEPI) in July 2024.
Chikungunya, transmitted by Aedes mosquitoes, leads to debilitating symptoms, significantly impacting affected regions' health systems. The disease has spread to over 110 countries since it re-emerged in 2004, with millions of reported cases, especially in the Americas. The rising economic burden on public health, compounded by climate change, underlines the urgency for effective intervention strategies such as vaccines.
Valneva specializes in developing innovative vaccines that address unmet medical needs. With this strategic realignment, the company can better focus its resources on ensuring the vaccine's availability globally. Meanwhile, SII continues its mission of delivering affordable vaccines to over 170 countries, further emphasizing the importance of global equity in health. Through its extensive vaccine portfolio, SII plays a crucial role in combating various infectious diseases, reinforcing the collaborative efforts required to address public health challenges faced by many regions.
This shift in partnership signifies an important step in public health responses, enhancing the ability to address chikungunya's growing threat effectively.
MWN-AI** Analysis
The recent termination of the chikungunya vaccine license agreement between Valneva SE and the Serum Institute of India (SII) is a significant development that investors should closely analyze. This mutual decision to part ways allows Valneva to regain full control over its vaccine supply chain and commercialization strategies, particularly in endemic high-risk areas. This strategic maneuver is crucial as Valneva aims to enhance access to its chikungunya vaccine in low- and middle-income countries, which aligns with its funding agreement with CEPI and the European Union.
Chikungunya, a mosquito-borne viral disease, has a widespread impact on public health, posing significant economic burdens. Given the disease's resurgence and its classification by the WHO as a major public health concern, Valneva's focus on direct control could lead to increased revenues from markets most affected by the virus. The potential for Valneva to scale up its production and distribution can enhance its financial performance and market position.
Despite the optimism, potential investors should remain vigilant regarding the risks associated with vaccine development and commercialization. Valneva faces challenges typical of biotech companies, such as regulatory approvals and competitive landscape dynamics. The company's track record of advancing vaccines through development phases is promising but does not guarantee future success.
Given the environmental factors exacerbating the spread of mosquito-borne diseases, the chikungunya vaccine market is ripe for growth. Investors looking for exposure to the biotech and healthcare sectors should consider Valneva’s position after regaining control of its chikungunya vaccine—a move that could yield long-term benefits. However, it is crucial to monitor regulatory progress and market response closely as developments unfold.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Saint-Herblain (France), Pune, (India), December 31, 2025 – Valneva SE (“Valneva” or “the Company”), a specialty vaccine company, and Serum Institute of India (SII), a Cyrus Poonawalla Group company today announced that they have mutually agreed to discontinue their license agreement for Valneva’s single-shot chikungunya vaccine.
Valneva´s strategic intent in regaining full rights is to assume direct control over its supply chain and commercialization for endemic high-risk countries, thereby accelerating access for regions most affected by the disease.
Supporting access to the vaccine in low-and-middle-income countries (LMICs) falls within the framework of the funding agreement Valneva signed with the Coalition for Epidemic Preparedness Innovations (CEPI) in July 2024 with co-funding from the European Union1.
About Chikungunya
Chikungunya virus (CHIKV) is a mosquito-borne viral disease spread by the bites of infected Aedes mosquitoes which causes fever, severe joint and muscle pain, headache, nausea, fatigue and rash. Joint pain is often debilitating and can persist for weeks to years1.
In 2004, the disease began to spread quickly, causing large-scale outbreaks around the world. Since the re-emergence of the virus, CHIKV has now been identified in over 110 countries in Asia, Africa, Europe and the Americas2. Between 2013 and 2023, more than 3.7 million cases were reported in the Americas3 and the economic impact is considered to be significant. The medical and economic burden is expected to grow with climate change as the mosquito vectors that transmit the disease continue to spread geographically. As such, the World Health Organization (WHO) has highlighted chikungunya as a major public health problem.4
About Valneva SE
We are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions.
We have a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently market three proprietary travel vaccines.
Revenues from our growing commercial business help fuel the continued advancement of our vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world’s most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against other global public health threats. More information is available at www.valneva.com.
About CEPI
CEPI was launched in 2017 as an innovative partnership between public, private, philanthropic and civil organisations. Its mission is to accelerate the development of vaccines and other biologic countermeasures against epidemic and pandemic disease threats and enable equitable access to them. CEPI has supported the development of more than 70 vaccine candidates or platform technologies against multiple known high-risk pathogens and is advancing the development of rapid response platforms for vaccines against a future Disease X. Central to CEPI’s pandemic-beating five-year plan for 2022-2026 is the ‘100 Days Mission’ to compress the time taken to develop safe, effective, globally accessible vaccines against new threats to just 100 days.
About Horizon Europe
Horizon Europe — #HorizonEU — is the European Union's flagship Research and Innovation programme, part of the EU-long-term Multiannual Financial Framework (MFF) with a budget of €95,5 billion to spend over a seven-year period (2021-2027). Under Horizon Europe, health research will be supported with the aim to find new ways to keep people healthy, prevent diseases, develop better diagnostics and more effective therapies, use personalised medicine approaches to improve healthcare and wellbeing, and take up innovative health technologies, such as digital ones.
About Serum Institute of India Private Limited
Serum Institute of India Pvt. Ltd, part of Cyrus Poonawalla Group is a global leader in vaccine manufacturing, dedicated to providing affordable vaccines worldwide. Present across 170+ countries, including the US, UK, and Europe, SIIPL holds the distinction of being the world's largest vaccine manufacturer. SIIPL's multifunctional production and one-of-the-largest facilities in Hadapsar & Manjari, Pune, with an annual capacity of 4 billion doses, has saved over 30 million lives over the years.
Founded in 1966, SIIPL's primary mission is to produce life-saving immunobiological drugs, with a particular emphasis on affordability and accessibility. Guided by a strong commitment to improving global health, the company has played a pivotal role in reducing the prices of essential vaccines, such as Diphtheria, Tetanus, Pertussis, HIB, BCG, r-Hepatitis B, Measles, Mumps, and Rubella. Notably, they are the manufacturers of 'Pneumosiil,' the world's most affordable PCV, 'Cervavac' the first indigenous qHPV vaccine in India, and R21/Matrix-M™, the second Malaria vaccine to be authorized for use in children in malaria-endemic regions, ‘MenFive’, the first in the world Pentavalent (ACYWX) Meningococcal Polysaccharide Conjugate Vaccine, approved and WHO-prequalified for use in the pediatric population. Moreover, SIIPL has been at the forefront of the global fight against COVID-19, delivering over 2 billion doses of the COVID-19 vaccine worldwide.
To further expand its global presence and ensure widespread vaccine availability, SIIPL has established Serum Life Sciences Ltd, a subsidiary in the UK and Serum Inc., a subsidiary in the US. Through relentless pursuit of innovation, SII continues to champion the cause of affordable vaccines, making a positive impact on the lives of millions worldwide. www.seruminstitute.com
| Valneva Investor and Media Contacts Laetitia Bachelot-Fontaine VP Global Communications & European Investor Relations M +33 (0)6 4516 7099 laetitia.bachelot-fontaine@valneva.com | Joshua Drumm, Ph.D. VP Global Investor Relations M +001 917 815 4520 joshua.drumm@valneva.com |
Forward-Looking Statements
This press release contains certain forward-looking statements relating to the business of Valneva, including with respect to use and regulatory review of existing products. In addition, even if the actual results or development of Valneva are consistent with the forward-looking statements contained in this press release, those results or developments of Valneva may not be sustained in the future. In some cases, you can identify forward-looking statements by words such as “could,” “should,” “may,” “expects,” “anticipates,” “believes,” “intends,” “estimates,” “aims,” “targets,” or similar words. These forward-looking statements are based largely on the current expectations of Valneva as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the expectations of Valneva could be affected by, among other things, uncertainties and delays involved in the development and manufacture of vaccines, unexpected clinical trial results or new adverse events, unexpected regulatory actions or delays, competition in general, currency fluctuations, the impact of the global and European credit crisis, and the ability to obtain or maintain patent or other proprietary intellectual property protection. Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made in this press release will in fact be realized. Valneva is providing this information as of the date of this press release and disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
1 https://jvi.asm.org/content/jvi/88/20/11644.full.pdf
2 https://cmr.asm.org/content/31/1/e00104-16
3 PAHO/WHO data: Number of reported cases of chikungunya fever in the Americas (Cumulative Cases 2018-2023 and Cases per year 2013-2017). https://www.paho.org/data/index.php/en/mnu-topics/chikv-en/550-chikv-weekly-en.html. Last accessed 01 Aug 2023.
4 Geographical expansion of cases of dengue and chikungunya beyond the historical areas of transmission in the Region of the Americas (who.int)
Attachment
FAQ**
How does the discontinuation of the license agreement between Valneva SE and Serum Institute of India (SII) impact Valneva SE INRLF's strategy to regain full rights over the chikungunya vaccine and its supply chain?
What are the potential economic implications for Valneva SE INRLF as it seeks to accelerate access to the chikungunya vaccine in endemic high-risk countries following the tie-up dissolution with SII?
In what ways will the funding agreement with CEPI influence Valneva SE INRLF's efforts to improve vaccine availability in low-and-middle-income countries (LMICs) after regaining commercialization rights?
Given the growing medical and economic burden of chikungunya, how does Valneva SE INRLF plan to leverage its expertise in specialty vaccines to address this public health challenge effectively?
**MWN-AI FAQ is based on asking OpenAI questions about Valneva SE (OTC: INRLF).
NASDAQ: INRLF
INRLF Trading
0.2% G/L:
$5.10 Last:
1,000 Volume:
$5.10 Open:
